A critical evaluation of the putative role of C3adesArg (ASP) in lipid metabolism and hyperapobetalipoproteinemia

Molecular Immunology

Volumn 36, Issue 13-14, 1999, Pages 869-876

  Kildsgaard, Jens ^a   Zsigmond, Eva ^a   Chan, Lawrence ^c   Wetsel, Rick A ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b Dept of Biochem and Molec Biology ^*  (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Acylation stimulating protein; Adipsin; ASP; C3a; Complement

Indexed keywords

ANAPHYLATOXIN; ARGININE; COMPLEMENT COMPONENT C3A; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ACYLATION; ADIPOCYTE; AUTOSOMAL DOMINANT DISORDER; COMPLEMENT ACTIVATION; CONFERENCE PAPER; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; HYPERLIPOPROTEINEMIA TYPE 2; LIPID METABOLISM; LYMPHOCYTE SUBPOPULATION; MEMBRANE BINDING; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ADIPOCYTES; ANIMALS; APOLIPOPROTEINS B; COMPLEMENT C3; COMPLEMENT C3A; COMPLEMENT FACTOR D; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPID METABOLISM; LIVER; MEMBRANE PROTEINS; MICE; MODELS, BIOLOGICAL; RECEPTORS, COMPLEMENT; SERINE ENDOPEPTIDASES; TRIGLYCERIDES;

EID: 0033379530     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(99)00108-X     Document Type: Conference Paper

References (58)

1. Ames R.S., Li Y., Sarau H.M., Nuthulaganti P., Foley J.J., Ellis C., Zeng Z., Su K., Jurewicz A.J., Hertzberg R.P., Bergsma D.J., Kumar C. Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J. Biol. Chem. 271:1996;20,231-20,234.
2. Baldo A., Sniderman A.D., St-Luce S., Zhang X.J., Cianflone K. Signal transduction pathway of acylation stimulating protein: involvement of protein kinase C. J. Lipid Res. 36:1995;1415-1426.
3. Baldo A., Sinderman A.D., St-Luce S., Avramoglu R.K., Maslowska M., Hoang B., Monge J.C., Bell A., Mulay S., Cianflone K. The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J. Clin. Invest. 92:1993;1543-1547.
4. Belmont H.M., Hopkins P., Edelson H.S., Kaplan H.B., Ludewig R., Weissmann G., Abramson S. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis. Rheum. 29:1986;1085-1089.
5. Bokisch V.A., Muller-Eberhard H.J. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J. Clin. Invest. 49:1970;2427-2436.
6. Castro Cabezas M., de Bruin T.W., de Valk H.W., Shoulders C.C., Jansen H., Willem Erkelens D. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J. Clin. Invest. 92:1993;160-168.
7. Chan L. Apolipoprotein B, the major protein component of triglyceride-rich and low density lipoproteins. J. Biol. Chem. 267:1992;25,621-25,624.
8. Charlesworth J.A., Peake P.W., Campbell L.V., Pussell B.A., O'Grady S., Tzilopoulos T. The influence of oral lipid loads on acylation stimulating protein (ASP) in healthy volunteers. Int. J. Obes. Relat. Metabl. Disord. 22:1998;1096-1102.
9. Choy L.N., Rosen B.S., Spiegelman B.M. Adipsin and an endogenous pathway of complement from adipose cells. J. Biol. Chem. 267:1992;12,736-12,741.
10. Choy L.N., Spiegelman B.M. Regulation of alternative pathway activation and C3a production by adipose cells. Obes. Res. 4:1996;521-532.
11. Cianflone K. Acylation stimulating protein and the adipocyte. J. Endocrinol. 155:1997;203-206.
12. Cianflone K. The acylation stimulating protein pathway: clinical implications. Clin. Biochem. 30:1997;301-312.
13. Cianflone K., Maslowska M. Differentiation-induced production of ASP in human adipocytes. Eur. J. Clin. Invest. 25:1995;817-825.
14. Cianflone K., Maslowska M., Sniderman A. The acylation stimulating protein-adipsin system. Int. J. Obes. Relat. Metab. Disord. 19:(Suppl. 1):1995;S34-S38.
15. Cianflone K., Maslowska M., Sniderman A.D. Acylation stimulating protein (ASP), an adipocyte autocrine: new directions. Semin. Cell. Dev. Biol. 10:1999;31-41.
16. Cianflone K., Rodriguez M.A., Walsh M., Vu H., Sniderman A.D. The effect of a plasma protein fraction on lipid synthesis in cultured skin fibroblasts from normals and patients with hyperapobetalipoproteinemia. Clin. Invest. Med. 11:1988;99-107.
17. Cianflone K., Roncari D.A., Maslowska M., Baldo A., Forden J., Sniderman A.D. Adipsin/acylation stimulating protein system in human adipocytes: regulation of triacylglycerol synthesis. Biochemistry. 33:1994;9489-9495.
18. Cianflone K., Vu H., Walsh M., Baldo A., Sniderman A. Metabolic response of acylation stimulating protein to an oral fat load. J. Lipid Res. 30:1989;1727-1733.
19. Cianflone K.M., Maslowska M.H., Sniderman A.D. Impaired response of fibroblasts from patients with hyperapobetalipoproteinemia to acylation-stimulating protein. J. Clin. Invest. 85:1990;722-730.
20. Cianflone K.M., Sniderman A.D., Walsh M.J., Vu H.T., Gagnon J., Rodriguez M.A. Purification and characterization of acylation stimulating protein. J. Biol. Chem. 264:1989;426-430.
21. Crass T., Raffetseder U., Martin U., Grove M., Klos A., Kohl J., Bautsch W. Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells. Eur. J. Immunol. 26:1996;1944-1950.
22. Flier J.S., Cook K.S., Usher P., Spiegelman B.M. Severely impaired adipsin expression in genetic and acquired obesity. Science. 237:1987;405-408.
23. Genest J., Sniderman A., Cianflone K., Teng B., Wacholder S., Marcel Y., Kwiterovich P. Jr. Hyperapobetalipoproteinemia. Plasma lipoprotein responses to oral fat load. Arteriosclerosis. 6:1986;297-304.
24. Germinario R., Sniderman A.D., Manuel S., Lefebvre S.P., Baldo A., Cianflone K. Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. Metabolism. 42:1993;574-580.
25. Hansson G.K., Holm J., Kral J.G. Accumulation if IgG and complement factor C3 in human arterial endothelium and atherosclerotic lesions. Acta. Pathol. Microbiol. Immunol. Scand. [A]. 92:1984;429-435.
26. Hollander W., Colombo M.A., Kirkpatric B., Paddock J. Soluble proteins in the human atherosclerotic plaque. With spectral reference to immunoglobulins, C3-complement component, alpha 1-antitrypsin and alpha 2-macroglobulin. Atherosclerosis. 34:1979;391-405.
27. Hugli T.E. Structure and function of C3a anaphylatoxin. Lambris J.D. The Third Component of Complement. vol. 153:1990;181-208 Springer-Verlag, Berlin-Heidelberg.
28. Kwiterovich P. Jr, Motevalli M., Miller M. Acylation-stimulatory activity in hyperapobetalipoproteinemic fibroblasts: enhanced cholesterol esterification with another serum basic protein, BP II. Proc. Natl. Acad. Sci. USA. 87:1990;8980-8984.
29. Kwiterovich P.O. Jr, Motevalli M., Miller M., Bachorik P.S., Kafonek S.D., Chatterjee S., Beaty T., Virgil D. Further insights into the pathophysiology of hyperapobetalipoproteinemia: role of basic proteins I, II, III. Clin. Chem. 37:1991;317-326.
30. Lesavre P.H., Hugli T.E., Esser A.F., Muller-Eberhard H.J. The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J. Immunol. 123:1979;529-534.
31. Mousli M., Hugli T.E., Landry Y., Bronner C. A mechanism of action for anaphylatoxin C3a stimulation of mast cells. J. Immunol. 148:1992;2456-2461.
32. Moxley G., Ruddy S. Elevated plasma C3 anaphylatoxin levels in rheumatoid arthritis patients. Arthritis. Rheum. 30:1987;1097-1104.
33. Murray I., Parker R.A., Kirchgessner T.G., Tran J., Zhang Z.J., Westerlund J., Cianflone K. Functional bioactive recombinant acylation stimulating protein is distinct from C3a anaphylatoxin. J. Lipid Res. 38:1997;2492-2501.
34. Muscari A., Bozzoli C., Puddu G.M., Sangiorgi Z., Dormi A., Rovinetti C., Descovich G.C., Puddu P. Association of serum C3 levels with the risk of myocardial infarction. Am. J. Med. 98:1995;357-364.
35. Porcel J.M., Ordi J., Castro-Salomo A., Vilardell M., Rodrigo M.J., Gene T., Warburton F., Kraus M., Vergani D. The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin. Immunol. Immunopathol. 74:1995;283-288.
36. Saleh J., Christou N., Cianflone K. Regional specificity of ASP binding in human adipose tissue. Am. J. Physiol. 276:1999;E815-E821. [in process citation].
37. Saleh J., Summers L.K., Cianflone K., Fielding B.A., Sniderman A.D., Frayn K.N. Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period. J. Lipid Res. 39:1998;884-891.
38. Scantlebury T., Maslowska M., Cianflone K. Chylomicron-specific enhancement of acylation stimulating protein and precursor protein C3 production in differentiated human adipocytes. J. Biol. Chem. 273:1998;20,903-20,909.
39. Schreiber R.D., Pangburn M.K., Lesavre P.H., Muller-Eberhard H.J. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc. Natl. Acad. Sci. USA. 75:1978;3948-3952.
40. Seifert P.S., Hugo F., Tranum-Jensen J., Zahringer U., Muhly M., Bhakdi S. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J. Exp. Med. 172:1990;547-557.
41. Singer L., Colten H.R., Wetsel R.A. Complement C3 deficiency: human, animal, and experimental models. Pathobiology. 62:1994;14-28.
42. Sniderman A., Shapiro S., Marpole D., Skinner B., Teng B., Kwiterovich P.O. Jr. Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins]. Proc. Natl. Acad. Sci. USA. 77:1980;604-608.
43. Sniderman A.D., Cianflone K. The adipsin-ASP pathway and regulation of adipocyte function. Ann. Med. 26:1994;388-393.
44. Sniderman A.D., Cianflone K. Metabolic disruptions in the adipocyte-hepatocyte fatty acid axis as causes of HyperapoB. Int. J. Obes. Relat. Metab. Disord. 19:(Suppl. 1):1995;S27-S33.
45. Sniderman A.D., Cianflone K. The adipsin-acylation-stimulating protein pathway and microenvironmental metabolic regulation. World Rev. Nutr. Diet. 80:1997;44-81.
46. Sniderman A.D., Cianflone K., Arner P., Summers L.K., Frayn K.N. The adipocyte, fatty acid trapping, and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 18:1998;147-151.
47. Sniderman A.D., Cianflone K., Frayn K. The pathogenetic role of impaired fatty acid trapping by adipocytes in generating the pleiotropic features of hyperapoB. Diabetologia. 40:(Suppl. 2):1997;S152-S154.
48. Sniderman A.D., Cianflone K., Summers L., Fielding B., Frayn K. The acylation-stimulating protein pathway and regulation of postprandial metabolism. Proc. Nutr. Soc. 56:1997;703-712.
49. Teng B., Forse A., Rodriguez A, Sniderman A. Adipose tissue glyceride synthesis in patients with hyperapobetalipoproteinemia. Can. J. Physiol. Pharmacol. 66:1988;239-242.
50. Teng B., Sniderman A.D., Soutar A.K., Thompson G.R. Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia. J. Clin. Invest. 77:1986;663-672.
51. Teng B., Thompson G.R., Sniderman A.D., Forte T.M., Krauss R.M., Kwiterovich P.O. Jr. Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia, and familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA. 80:1983;6662-6666.
52. Torzewski J., Bowyer D.E., Waltenberger J., Fitzsimmons C. Processes in atherogenesis: complement activation. Atherosclerosis. 132:1997;131-138.
53. Vlaicu R., Rus H.G., Niculescu F., Cristea A. Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis. 55:1985;35-50.
54. Wetsel R.A., Kildsgaard J., Zsigmond E., Liao W., Chan L. Genetic deficiency of acylation stimulating protein (ASP/C3adesArg (ASP)) does not cause hyperapobetalipoproteinemia in mice. J. Biol. Chem. 274:1999;19,429-19,433.
55. White R.T., Damm D., Hancock N., Rosen B.S., Lowell B.B., Usher P., Flier J.S., Spiegelman B.M. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J. Biol. Chem. 267:1992;9210-9213.
56. Yasruel Z., Cianflone K., Sniderman A.D., Rosenbloom M., Walsh M., Rodriguez M.A. Effect of acylation stimulating protein on the triacylglycerol synthetic pathway of human adipose tissue. Lipids. 26:1991;495-499.
57. Ylitalo K., Porkka K.V., Meri S., Nuotio I., Suurinkeroinen L., Vakkilainen J., Pajukanta P., Viikari J.S., Peltonen L., Ehnholm C., Taskinen M.R. Serum complement and familial combined hyperlipidemia. Atherosclerosis. 129:1997;271-277.
58. Zhang X.J., Cianflone K., Genest J., Sniderman A.D. Plasma acylation stimulating protein (ASP) as a predictor of impaired cellular biological response to ASP in patients with hyperapoB. Eur. J. Clin. Invest. 28:1998;730-739.